OMTN, Volume *23*

Supplemental Information

Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling

Yasuhiro Kazuki, Narumi Uno, Satoshi Abe, Naoyo Kajitani, Kanako Kazuki, Yuwna Yakura, Chiaki Sawada, Shuta Takata, Masaki Sugawara, Yuichi Nagashima, Akane Okada, Masaharu Hiratsuka, Mitsuhiko Osaki, Giulia Ferrari, Francesco Saverio Tedesco, Satoshi Nishikawa, Ken Fukumoto, Shin-ichiro Takayanagi, Atsushi Kunisato, Shin Kaneko, Mitsuo Oshimura, and Kazuma Tomizuka



Figure S1 Characterization of DMD-iPSCs induced by a Sendai virus vector with Yamanaka factors.

(A) QH staining of DMD-iPSC lines. (B) Multiplex PCR analysis of DMD-iPSC lines and normal human fibroblasts (HFL1). (C) Immunofluorescence staining using an anti-SeV polyclonal antibody in the DMD-iPSC line.



Figure S2 Transfer of DYS-HAC2 into DMD-iPSCs via MV-MMCT using three types of MV-H protein (CD46, CD9, and CD71).



Figure S3 Characterization of DMD-iPS DYS-HAC2-derived HIDEMs by FCM.



Figure S4 Schematic diagram of the generation of versatile T-iPSCs with the basal-HAC.

Table S1 Summary for type of MV-H and PCR results in DMD-iPS (DYS-HAC) clones obtained via MV-MMCT

Clone No.	Type of MV-H	NeoF/DloxP3L
1	CD9	+
2	CD9	+
3	CD9	-
4	CD9	+
5	CD46	+
6	CD46	+
7	CD46	+
8	CD46	+
9	CD71	+
10	CD71	-
11	CD71	-
12	CD71	-
13	CD71	+
14	CD9	-
15	CD9	+
16	CD9	-
17	CD9	+
18	CD9	+
20	CD46	-
21	CD46	+
23	CD46	-
26	CD71	-
27	CD71	-
29	CD71	-
30	CD71	-
31	CD71	+
32	CD46	-

Table S2 Summary for PCR results in T-iPS clones with KO1 (Kusabira Orange 1)

T-iPS clone No.	EF1a Fw/NeoR Rv
KO1	+
KO2	+
KO3	+
KO4	+
KO5	+
KO6	+
KO7	+
Basal-HAC	-
modified 21HAC2	-